BioSpace News Archive

Eisai Co., Ltd. and Biogen Inc. announced that an application for manufacturing and marketing approval for lecanemab, an anti-amyloid-β protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare.

Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation of the National Medical Products Administration has accepted its New Drug Application for Zorifertinib, a next-generation EGFR-TKI specially designed to treat advanced EGFR-mutated non-small cell lung cancer patients with central nervous system metastases.

BioArctic AB’s partner Eisai announced that the application for manufacturing and marketing approval for lecanemab in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare.